Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis

    T category (T3,4 vs. T1,2)   N category (H vs. L)   M category (H vs. L)   Grade (G3 vs. G1,2)   DFS (death vs. survive)   OS 3 year (death vs. survive)   OS 5 year (death vs. survive)
   N1 RR(95% CI) N2 RR(95% CI) N3 RR(95% CI) N4 RR(95% CI) N5 RR(95% CI) N6 RR(95% CI) N7 RR(95% CI)
Over all   13 1.15 (0.97, 1.35) 23 1.39 (1.07, 1.81) 4 1.79 (0.76, 4.26) 7 1.47 (1.00, 2.14) 5 1.50 (0.83, 2.71) 10 0.76 (0.59, 0.99) 12 0.76 (0.55, 1.05)
Cancer type                
Oral   2 0.75 (0.48, 1.16) 9 0.82 (0.54, 1.25) 2 1.99 (0.99, 3.99) 2 0.91 (0.50, 1.67) 4 1.86 (1.47, 2.37) 3 0.85 (0.49, 1.47) 5 0.91 (0.46, 1.78)
Larynx   8 1.33 (1.01, 1.76) 11 2.53 (1.99, 3.21) - - 4 2.13 (0.99, 4.58) - - 5 0.87 (0.62, 1.23) 5 0.62 (0.47, 0.83)
Pharynx & Larynx   11 1.21 (1.08, 1.35) 14 1.95 (1.35, 2.82) 2 1.77 (0.13, 23.59) 5 1.71 (1.04, 2.79) 1 0.53 (0.29, 0.97) 7 0.72 (0.52, 0.99) 7 0.66 (0.47, 0.94)
Geographic area                
Asia Over all 9 1.39 (1.17, 1.64) 16 1.81 (1.26, 2.61) 3 1.82 (0.59, 5.63) 6 1.61 (1.01, 2.57) 2 0.98 (0.28, 3.4) 4 0.71 (0.56, 0.89) 4 0.8 (0.57, 1.14)
Oral -   3 0.75 (0.10, 5.62) 1 2.03 (0.99, 4.17) 1 0.72 (0.02, 4.33) 1 1.87 (0.9, 3.88) - - - -
Larynx 6 1.60 (1.14, 2.25) 10 2.39 (1.65, 3.45) - - 4 2.13 (0.99, 4.58) - - 3 0.77 (0.66, 0.9) 3 0.69 (0.52, 0.91)
Larynx & pharynx 9 1.39 (1.17, 1.64) 13 1.98 (1.33, 2.95) 2 1.77 (0.13, 23.59) 5 1.71 (1.04, 2.79) 1 0.53 (0.29, 0.97) 4 0.71 (0.56, 0.89) 4 0.8 (0.57, 0.94)
Europe & USA Over all 3 0.88 (0.76, 1.02) 6 0.90 (0.68, 1.20) 1 1.46 (0.09, 22.93) 1 1.03 (0.56, 1.92) 2 3.08 (0.74, 12.78) 6 0.78 (0.48, 1.27) 8 0.64 (0.35, 1.16)
Oral 1 0.57 (0.30, 1.11) 5 0.73 (0.52, 1.02) 1 1.46 (0.09, 22.93) 1 1.03 (0.56, 1.92) 2 3.08 (0.74, 12.78) 3 0.85 (0.49, 1.47) 5 0.90 (0.46, 1.78)
Larynx 2 0.96 (0.85, 1.08) 1 1.85 (1.07, 3.18) - - - - - - 2 0.96 (0.24, 3.88) 2 0.46 (0.29, 0.72)
Larynx & pharynx 2 0.96 (0.85, 1.08) 1 1.85 (1.07, 3.18) - - - - - - 3 0.61 (0.15, 2.5) 3 0.36(0.23, 0.57)
Oral Pan-CD44 2 0.75 (0.48, 1.16) 3 0.58 (0.37, 0.92) 2 1.99 (0.99, 3.99) 2 0.91 (0.5, 1.67) 2 1.65 (1.68, 2.13) 3 0.85 (0.49, 1.47) 4 0.69 (0.32, 1.52)
  CD44-6 - - 2 0.79 (0.29, 2.12) - - - - - - - - - -
Larynx Pan-CD44 5 1.25 (0.90, 1.73) 6 2.83 (2.01, 3.98) 2 - 4 2.13 (0.99, 4.58) - - 5 0.87 (0.62, 1.23) 3 0.66 (0.46, 0.95)
  CD44-6 2 1.34 (0.99, 1.82) 4 1.92 (1.39, 2.64) - - - - - - - - 2 0.53 (0.37, 0.77)
Larynx & pharynx Pan-CD44 6 1.23 (0.92, 1.65) 7 2.74 (1.98, 3.81) 1 6.65 (0.93, 47.63) 4 2.13 (0.99, 4.58) 1 0.53 (0.29, 0.97) 6 0.794 (0.56, 1.1) 4 0.56 (0.34, 0.93)
  CD44-6 3 1.15 (0.90, 1.48) 5 1.47 (0.90, 2.42) 1 1.03 (0.94, 1.13) - - - - - - 2 0.53 (0.37, 0.77)
Sample size a <58.5 4 1.79 (0.82, 3.89) 10 1.388 (0.83, 2.33) 1 6.65 (0.93, 47.63) 3 1.34 (0.5, 3.58) 3 1.71 (0.44, 6.69) 3 0.34 (0.21, 0.54) 6 0.55 (0.22, 1.37)
  ≥58.5 9 1.03 (0.91, 1.17) 13 1.40 (1.01, 1.95) 3 1.62 (0.87, 3.03) 4 1.62 (0.91, 2.88) 2 1.65 (1.28, 2.13) 7 0.91 (0.69, 1.2) 6 0.80 (0.57, 1.13)
Follow time(month) b <68.5 7 1.04 (0.89, 1.20) 8 1.29 (0.80, 2.10) 2 4.51 (0.96, 21.13) 5 1.42 (0.96, 2.08) 5 1.50 (0.83, 2.71) 7 0.88 (0.66, 1.17) 8 0.89 (0.62, 1.28)
  ≥68.5 6 1.37 (0.94, 2.01) 15 1.45 (1.03, 2.05) 2 1.28 (0.36, 4.50) 2 1.27 (0.11,14.01) - - 3 0.39 (0.25, 0.62) 4 0.43 (0.29, 0.65)
  1. a: median of sample size for each study.
  2. b: median of follow-up time for each study.
  3. H: high expression; L: low expression; DFS: disease free survival; OS: overall survival.